RxDoctor Payments Data

Michael Kemper, MD

Urology · Decatur, GANPI 1255746871

Payments from drug & device makers

What this record shows

This record is dominated by grants: $50,000 of the $72,439 with a category attached, or 69.0%. Boston Scientific accounts for 79.9% of it on its own, with 42 other manufacturers making up the rest. Reporting peaked in 2019 at $53,939 and has fallen 96.3% since, to $1,995 in 2025. Among urology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$72,439in general payments, 2019–2025

Across 416 payments — averaging $174.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$58K
  • Coloplast$4K
  • Teleflex LLC$3K
  • Axonics, Inc.$2K
  • Endo Pharmaceuticals Inc.$1K
  • Astellas Pharma US Inc$611
  • plus $4K from 37 others

What the payments were for

  • Grants$50,00069%
  • Travel & lodging$4,8897%
  • Food & beverage$17,42124%
  • Education$1290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$72,439 in reported general payments places this provider in the 95th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia

Medicare billing

Part B allowed, 2024
$219,770
Medicare patients
403
Services billed
3,667

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide73$1,060,163
NubeqaDarolutamide32$421,322
XtandiEnzalutamide18$280,319
MyrbetriqMirabegron87$105,900
GemtesaVibegron93$83,455
Alfuzosin Hcl ErAlfuzosin Hcl230$4,606
Tamsulosin Hcl420$4,421
Dutasteride82$3,975
Tolterodine Tartrate ErTolterodine Tartrate36$2,514
Solifenacin Succinate47$1,972
Estradiol25$1,614
Trospium Chloride33$1,529
Methenamine Hippurate17$1,435
Tolterodine Tartrate14$1,168
Testosterone Cypionate21$1,137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$225$1,060,16373 claims
BayerNubeqa$406$421,32232 claims
Astellas Pharma US IncXtandi, Myrbetriq$611$386,219105 claims
Sumitomo Pharma America, Inc.Gemtesa$305$83,45593 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 369 urology providers in Georgia.

Other urology in Decatur

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →